Alkermes
development candidates emerging from platform mechanism programs and potential indications selective inhibitors pro synaptic orphan indications in and neurodegenerative disorders follow on candidate non orphan indications in neurodegenerative and neuropsychiatric spaces increase of and pro synaptic frontotemporal dementia with precursor mutations and other variants restoration of abnormal receptor agonist narcolepsy and indications with excessive daytime sleepiness fatigue or attention cognition issues histone repressor of repressor element silencing transcription factor | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
51 of 144
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io